Sarepta Therapeutics and Alnylam Pharmaceuticals have announced the pricing of $1 billion and $900 million in convertible senior notes respectively.
Sarepta Therapeutics and Alnylam Pharmaceuticals have announced the pricing of $1 billion and $900 million in convertible senior notes respectively.
Among other objectives, Sarepta plans to use the funds to repay borrowings and accrued and unpaid interest and for general corporate purposes, the company shared in a statement.
Sarepta indicated the aggregate principal amount of the notes will mature on Sept. 15, 2027. Unless the company redeems them before then, they are repurchased or converted.
The notes are only being offered to people the company believes to be qualified institutional buyers. Sarepta expects to grant the initial buyers of the notes the option to purchase up to another $150 million in notes.
A senior convertible note is a debt security that carries the option for the note to be converted into a pre-set amount of the issuer’s shares. A debt security is an investment asset that involves debt instead of ownership in the company. A senior convertible note also offers investors the chance to earn interest.
Sarepta is best known for its Duchenne muscular dystrophy (DMD) therapies. Its currently marketed therapeutics in the space are Exondys 51 (eteplirsen), Vyondys 53 (golodirsen) and Amondys 45 (casimersen).
In August, Sarepta announced plans to submit SRP-9001 (delandistrogene moxeparvovec), a gene therapy for DMD, to regulators within the next few months - eyeing a mid-2023 launch. The original plan had been to submit in 2023.
Sarepta and partner Roche presented promising functional data from several trials of the gene therapy in July.
Alnylam Seeks $900K
The conditions for Alnylam’s pricing are similar to Sarepta’s, which are due on Sept. 15, 2027. The company plans to grant the initial buyers of the notes an option to buy an additional $135 million in notes within 13 days starting on the date the notes are first issued.
Alnylam said it plans to enter into privately negotiated capped call transactions with at least one but potentially more of the initial buyers or their affiliates or financial institutions.
Alnylam plans to use the net proceeds “to pay down our term loan in full, including termination payment,” Chris Buckley, associate director of investor relations & corporate communications for Alnylam, told BioSpace. This includes paying the cost of the capped call transaction and general corporate purposes.
Buckley added, “We made a strategic and opportunistic decision to issue convertible notes in order to repay existing high-cost floating rate debt (current interest coupon payments at 10%+).”
In addition, “this transaction improves our financial flexibility by replacing secured debt with unsecured debt that carries no financial covenants,” Buckley said.
The move offers Alnylam the most efficient and low-cost option to refinance its existing interest Blackstone debt of more than 7%, leading to a “dramatic reduction in interest expense versus the existing debt,” Buckley said.
Last week, Alnylam reported data from the APOLLO-B trial of patisiran in transthyretin-mediated (ATTR) amyloidosis patients with cardiomyopathy.
The data showed improved functional capacity in this patient popluation. Alnylam plans to file a Supplemental New Drug Application in this indication later this year.
